title: Sevelamer and CKD-associated cardiovascular disease: going further, but far from there.
abstract: Cardiovascular disease is a major complication of chronic kidney disease (CKD), and current data support its link to mineral metabolism disturbances. However, there is an intense debate over whether CKD-mineral and bone disorder therapy could change the cardiovascular burden in CKD. The study by Maizel and colleagues shows the benefits of a phosphate binder, sevelamer, for the progression of aortic stiffness and endothelial dysfunction as well as left ventricular dysfunction and hypertrophy in mice with CKD.
authors.affiliation: Nephrology Division, Universidade de São Paulo, São Paulo, Brazil. rosa.moyses@uol.com.br
authors.forename: Rosa M A
authors.initials: RM
authors.lastname: Moysés
authors.forename: Maria E F
authors.initials: ME
authors.lastname: Canziani
mesh_terms: D000818:Animals; D002319:Cardiovascular System / Q000187:drug effects*; D005260:Female; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D011073:Polyamines / Q000494:pharmacology* / Q000627:therapeutic use*; D000069603:Sevelamer; D059289:Vascular Stiffness / Q000187:drug effects*
chemical_list: D011073:Polyamines; D000069603:Sevelamer